Menu Search
Equities

Abbott India Ltd

ABBOTINDIA:NSI

Abbott India Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)27,686.80
  • Today's Change566.80 / 2.09%
  • Shares traded5.81k
  • 1 Year change+15.89%
  • Beta0.1319
Data delayed at least 15 minutes, as of Nov 22 2024 09:49 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy2
Outperform2
Hold0
Sell0
Strong Sell0

Share price forecast in INR

The 3 analysts offering 12 month price targets for Abbott India Ltd have a median target of 31,000.00, with a high estimate of 32,700.00 and a low estimate of 27,780.00. The median estimate represents a 14.31% increase from the last price of 27,120.00.
High20.6%32,700.00
Med14.3%31,000.00
Low2.4%27,780.00

Dividends

In 2024, Abbott India Ltd reported a dividend of 410.00 INR, which represents a 127.78% increase over last year. The 4 analysts covering the company expect dividends of 405.84 INR for the upcoming fiscal year, a decrease of 1.02%.
Div growth (TTM)127.78%
More ▼

Earnings history & estimates in INR

On Feb 10, 2023, earnings of 116.16 per share. This result was in line with the expectation of the one analyst following the company
The next earnings announcement is expected on May 07, 2025.
Average growth rate+6.37%
Abbott India Ltd reported annual 2024 earnings of 565.28 per share on May 09, 2024.
Average growth rate+19.38%
More ▼

Revenue history & estimates in INR

Abbott India Limited had 2nd quarter 2025 revenues of 16.33bn. This bettered the 16.29bn consensus of the 2 analysts covering the company. This was 10.39% above the prior year's 2nd quarter results.
Average growth rate+2.34%
Abbott India Limited had revenues for the full year 2024 of 58.49bn. This was 9.35% above the prior year's results.
Average growth rate+9.38%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.